B. Riley Securities Downgrades Cognition Therapeutics to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has downgraded Cognition Therapeutics (NASDAQ:CGTX) from Buy to Neutral and lowered the price target from $5 to $1.
August 06, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B. Riley Securities downgraded Cognition Therapeutics from Buy to Neutral and reduced the price target from $5 to $1, indicating a less optimistic outlook for the stock.
The downgrade from Buy to Neutral and the significant reduction in the price target from $5 to $1 by B. Riley Securities suggests a negative short-term outlook for Cognition Therapeutics. This is likely to result in a decline in the stock price as investors react to the less favorable analyst rating and lower price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100